Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 6/20 | 0.66 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.61 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.61 |
| ▸ | NOTCH1 | P46531 | 3/20 | 0.58 |
| ▸ | NOTCH3 | Q9UM47 | 3/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016397 | 0.91 | CCKBR (0.65) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5016293 | 0.88 | CCKBR (0.69) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5022594 | 0.87 | PSEN1 (0.66) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5016371 | 0.87 | PSEN1 (0.73) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4991958 | 0.87 | PSEN1 (0.78) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5016379 | 0.85 | CCKBR (0.78) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5026491 | 0.84 | CCKBR (0.67) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5018003 | 0.83 | CCKBR (0.69) | CCKBRSCN9AKCNH2 | |
| SCHEMBL4992875 | 0.82 | PSEN1 (0.78) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5026356 | 0.82 | CCKBR (0.70) | CCKBRPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592684-B1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7375099-B2 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | CCKBR 916/4885PSEN1 4/4885PSEN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.